ArticleJournal of the Endocrine Society2025
25(OH) Vitamin D Levels and Severity of Type 1 Diabetes in Youth and Adults With Recent-Onset Disease.
Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Vitamin DFrontiers in immunology · 2026Review
- Combined Use of Vitamin D and DPP-4 Inhibitors as a Potential Adjuvant Treatment Strategy to Enhance the Efficacy of Novel Beta-Cell Replacement Therapies for Type 1 Diabetes.Medical sciences (Basel, Switzerland) · 2025Review
- Type 1 Diabetes Autoimmunity: To What Extent Vitamin D is Beneficial.Biochemistry research international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To test 25-hydroxy vitamin D (25(OH)D) levels among subjects with new-onset type 1 diabetes (T1D) and their association with fasting and stimulated C-peptide at study entry in an open-label randomized trial. Methods: We conducted a post hoc secondary analysis of the POSEIDON trial (a Pilot, Safety and Feasibility Trial of High-Dose Omega-3 fatty acids and High-Dose Cholecalciferol Supplementation in Type 1 Diabetes). Eligibility criteria included age 6 to 65 years, T1D of up to 10 years duration, presence of at least 1 islet autoantibody, and stimulated C-peptide ≥0.066 pmol/mL. A total of 18 subjects with new-onset T1D (defined as ≤180 days duration) with paired 25(OH)D levels and a 4-hour mixed meal tolerance test (MMTT) at screening were included. Results: 25(OH)D levels were directly associated with fasting C-peptide ( Conclusion: 25(OH)D levels were directly associated with fasting C-peptide in youth and adults with newly diagnosed T1D. Low 25(OH)D levels may be associated with more aggressive autoimmunity in patients at risk for T1D potentially leading to a lower beta-cell mass at T1D clinical onset, but larger studies are required to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.